New Enterprise Associates Reduces Stake in Monte Rosa Therapeutics to 7.9%
GLUE has more than doubled off its 52-week low of $4.12.
Summary
Major institutional investor New Enterprise Associates has reduced its stake in Monte Rosa Therapeutics to 7.9% through a share distribution, signaling a decreased investment.
Key Events · Ownership and Investor Activity · GLUE
-
Institutional Stake Reduced
New Enterprise Associates (NEA) has reduced its beneficial ownership in Monte Rosa Therapeutics, Inc. to 7.9% of the outstanding common stock.
-
Pro Rata Share Distribution
NEA 17 executed a pro rata distribution of 1,000,000 shares of common stock to its general and limited partners for no consideration on July 1, 2026.
-
Subsequent Open Market Sale
Following the distribution, an entity associated with NEA's Executive Committee sold 11,830 shares on the open market at a weighted average price of $24.18 per share on July 2, 2026.
-
Multiple Individuals Cease 5% Ownership
Several individuals associated with NEA, including Forest Baskett, Ali Behbahani, Carmen Chang, Edward T. Mathers, Paul Walker, and Rick Yang, ceased to beneficially own 5% or more of the Issuer's common stock as of April 1, 2026.
Analysis · GLUE · Life Sciences
New Enterprise Associates (NEA), a significant institutional investor, has reduced its beneficial ownership in Monte Rosa Therapeutics to 7.9% of outstanding shares. This reduction, primarily through a pro rata distribution of 1,000,000 shares to its partners, signals a decreased commitment or a strategic portfolio rebalancing away from the company. This follows a broader trend of insider distribution, as indicated by recent Form 144 filings.
How filings like this one have moved
In the 30 days to Sep 12, 2026, 29.9% of the 1939 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.15%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, GLUE was trading at $23.25 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2B. The 52-week trading range was $4.12 to $25.77. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.